HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA Again Stops At Qualified Health Claim For Supplements: Cranberry Reduces UTI Risk

Executive Summary

FDA intends to exercise enforcement discretion regarding QHCs about the association between reduced risk of recurrent UTI and use of supplements with at least 500 mg cranberry fruit powder and of cranberry juice beverages containing at least 27% cranberry juice.

You may also be interested in...



STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.

US Process Modeled On OTC Review Could Improve Supplement Health Claim Requests’ Chances

Claims supplements could be stronger, says a veteran food and supplement industry attorney, if FDA would give appropriate credit to the scientific evidence that firms are providing with their requests to use unqualified health claims.

Omega-3 Heart Health Claims Decision: FDA Out Of Step With Industry?

"The reality is that the FDA remains unwilling to rely upon a meta-analysis of only the highest quality studies in order to guide its final decision," GOED VP Harry Rice. "I think FDA has really lost sight of how the dietary supplement industry has changed," says attorney Charles Jolly.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel